Drug Trial Radar · NCT04920786
Sequential Dose-escalation Study to Assess the Safety, Tolerability and Pharmacokinetics of TB006 in Healthy Subjects
Last checked: Nov 19, 2026Latest source record: Dec 9, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
48
Actual
Start
Jun 1, 2021
Primary completion
May 3, 2022
Study completion May 3, 2022
Sponsor
- Lead sponsor
- TrueBinding, Inc.Industry
- Sponsor type
- Industry
- First posted
- Jun 10, 2021
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This is a single dose, dose-escalation study to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of TB006, a monoclonal antibody that will be studied as a disease modifying treatment for Alzheimer's disease.
Conditions
- Alzheimer Disease
Interventions
TB006Drug
TB006
Sterile saline (Placebo)Other
Sterile saline
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of subjects and rate of treatment-emergent adverse events, graded by CTCAE Version 5.0, by dose group and all active treatment vs. placeboTime frame: Day1-Day 75
- To determine the single-dose PK profile of TB006 in healthy adult subjectsTime frame: Through day 75
- To determine the MTD of single doses of TB006 in healthy adult subjectsTime frame: Through day 75
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Collaborative Neuroscience Research, LLC (CNS)
Long Beach, California
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.